Please join the Antitrust Section for the Annual Fall Antitrust
and Myriad Genetics Decisions: Is
Competition Policy Trumping IP Protection at the Supreme Court?
October 30, 2013
8:30 a.m. – 11:00 a.m.
The Harvard Club, Cambridge Room
35 West 44th Street, New York,
Free Admission - 1.5 CLE credits Breakfast
will be served
The Antitrust Section’s Fall Antitrust
Symposium features the top legal scholars in the nation on the most cutting
edge legal issue of the day – the intersection of the antitrust and
intellectual property laws. Last term, the
Supreme Court handed down two pivotal decisions on the patent/antitrust
interface: Actavis, which addresses
the legality of patent settlements that include a so-called “reverse payment,”
and Myriad Genetics, which addresses
the patentability of isolated human DNA.
Issues to be considered and debated by our panel of experts include:
- The effects of Actavis on antitrust liability for conduct within the scope of
- The implications of Myriad Genetics with respect to evolving standards for
- The decisions’ impact on the incentives of
pharmaceutical and biotechnology firms to innovate and create new products;
- Whether these decisions represent a trend in the
Supreme Court towards favoring competition policy concerns at the expense
of IP protection.
Andrew I. Gavil*
Office of Policy Planning, Federal Trade Commission
of Law, Howard University School of Law (on leave)
C. Scott Hemphill
of Law, Columbia Law School
Emily Michiko Morris
Professor of Law, Indiana University Robert H. McKinney School of Law
Kannon K. Shanmugam
and Head of Appellate Practice, Williams & Connolly LLP
Eric J. Stock
of the Antitrust Law Section of the New York State Bar Association
Chief of the Antitrust Bureau of the New York Attorney General’s
* Mr. Gavil’s
participation is dependent on the end of the federal government shutdown.
For more information or to register, contact Section Liaison Tiffany Bardwell.